Literature DB >> 309922

The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity.

M J Berendt, R J North, D P Kirstein.   

Abstract

It was shown that of four syngeneic, murine tumors investigated, only those that evoked the generation of a state of concomitant anti-tumor immunity were susceptible to endotoxin-induced regression. Moreover, the temporal relationship between the generation of concomitant immunity and the onset of susceptibility to endotoxin-induced regression points to the likely possibility that tumor regression depends on the preceding acquisition of the specifically-sensitized, effector T cells that express concomitant immunity. It is suggested that endotoxin-induced hemorrhagic necrosis which invariably precedes tumor regression serves to create conditions inside the tumor that are conducive to the entry and the functioning of effector T cells. It is also suggested that tumor necrosis factor causes hemorrhagic necrosis rather than tumor regression.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 309922      PMCID: PMC2185097          DOI: 10.1084/jem.148.6.1560

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  8 in total

1.  Metastasis results from preexisting variant cells within a malignant tumor.

Authors:  I J Fidler; M L Kripke
Journal:  Science       Date:  1977-08-26       Impact factor: 47.728

Review 2.  Induction and immunological properties of tumor necrosis factor.

Authors:  M K Hoffmann; H F Oettgen; L J Old; R S Mittler; U Hammerling
Journal:  J Reticuloendothel Soc       Date:  1978-04

3.  Corynebacterium parvum as the priming agent in the production of tumor necrosis factor in the mouse.

Authors:  S Green; A Dobrjansky; M A Chiasson; E Carswell; M K Schwartz; L J Old
Journal:  J Natl Cancer Inst       Date:  1977-11       Impact factor: 13.506

4.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

5.  Nature of "memory" in T-cell-mediated antibacterial immunity: anamnestic production of mediator T cells.

Authors:  R J North
Journal:  Infect Immun       Date:  1975-10       Impact factor: 3.441

6.  Partial purification of a serum factor that causes necrosis of tumors.

Authors:  S Green; A Dobrjansky; E A Carswell; R L Kassel; L J Old; N Fiore; M K Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1976-02       Impact factor: 11.205

7.  The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity.

Authors:  M J Berendt; R J North; D P Kirstein
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

8.  T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites.

Authors:  R J North; D P Kirstein
Journal:  J Exp Med       Date:  1977-02-01       Impact factor: 14.307

  8 in total
  24 in total

1.  Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.

Authors:  T D Armstrong; V K Clements; B K Martin; J P Ting; S Ostrand-Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

Review 2.  Modulation of antitumor immunity--immunobiologic approaches.

Authors:  R J North; E S Dye; C D Mills; J P Chandler
Journal:  Springer Semin Immunopathol       Date:  1982

3.  Generation of enhanced macrophage-mediated antibacterial resistance in animals responding to tumor allografts.

Authors:  M F Newborg; R J North
Journal:  Infect Immun       Date:  1982-01       Impact factor: 3.441

4.  Role of histamine in the antitumour activity of endotoxin.

Authors:  N Bloksma; P van de Wiel; F Hofhuis; F Kuper; J Willers
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

5.  Muramyl dipeptide is a powerful potentiator of the antitumor action of various tumor-necrotizing agents.

Authors:  N Bloksma; F M Hofhuis; J M Willers
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

6.  Muramyl dipeptide analogues as potentiators of the antitumor action of endotoxin.

Authors:  N Bloksma; F M Hofhuis; J M Willers
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Hypoxic tumor cell death and modulation of endothelial adhesion molecules in the regression of granulocyte colony-stimulating factor-transduced tumors.

Authors:  M P Colombo; L Lombardi; C Melani; M Parenza; C Baroni; L Ruco; A Stoppacciaro
Journal:  Am J Pathol       Date:  1996-02       Impact factor: 4.307

8.  Endotoxin-mediated necrosis and regression of established tumours in the mouse. A correlative study of quantitative changes in blood flow and ultrastructural morphology.

Authors:  G G MacPherson; R J North
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

9.  Subtherapeutic numbers of tumour-sensitized, L3T4+, Ly 1+2- T cells are needed for endotoxin to cause regression of an established immunogenic tumour.

Authors:  A Digiacomo; R J North
Journal:  Immunology       Date:  1987-03       Impact factor: 7.397

10.  Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours.

Authors:  L M Ching; W R Joseph; L Zhuang; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.